
## CDK-IN-9

| Cat. No.:          | HY-150641   |  |  |  |
|--------------------|---|--|--|--|
| Molecular Formula: | $C_{21}H_{24}N_{8}S$  |  |  |  |
| Molecular Weight:  | 420.53  |  |  |  |
| Target:            | CDK; Apoptosis; DNA/RNA Synthesis   |  |  |  |
| Pathway:           | Cell Cycle/DNA Damage; Apoptosis  |  |  |  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |  |  |  |



| BIOLOGICAL ACTIVITY       |   |                                       |                                      |                                      |  |
|---------------------------|---|---------------------------------------|--------------------------------------|--------------------------------------|--|
| Description               | CDK-IN-9 (compound 24) is a potent CDK inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC <sub>50</sub> values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II <sup>[1]</sup> .  |                                       |                                      |                                      |  |
| IC <sub>50</sub> & Target | CDK2/E<br>4 nM (IC <sub>50</sub> )  | Cdk5/p25<br>39 nM (IC <sub>50</sub> ) | CDK9/T1<br>20 nM (IC <sub>50</sub> ) | CDK12/K<br>64 nM (IC <sub>50</sub> ) |  |
|                           | CDK13/K<br>22 nM (IC <sub>50</sub> )  |                                       |                                      |                                      |  |
| In Vitro                  | CDK-IN-9 (compound 24) (0.005, 0.05, 0.5, or 5 μM; 2 h) potently decreases the level of cyclin K in MINO cells at 5 nM, and makes cyclin K disappear completely at 50 nM <sup>[1]</sup> .<br>CDK-IN-9 makes siRNA silencing of DDB1 effectively stabilizes cyclin K at the protein level in treated MINO cells <sup>[1]</sup> .<br>CDK-IN-9 (2.5-40 nM; 24 h) activates caspases 3/7/9 and decreases anti-apoptotic proteins Mcl-1 and XIAP in MINO cells <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |                                       |                                      |                                      |  |
| In Vivo                   | CDK-IN-9 (0.1-10 mg/kg; IP, single dosage) causes the decrease in cyclin K and CDK12 levels <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |                                       |                                      |                                      |  |

## REFERENCES

[1]. Jorda R, et al. 3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders. J Med Chem. 2022 Jul 14;65(13):8881-8896.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

